MA51679A - Composés destinés au traitement de troubles dépendant de la kinase - Google Patents
Composés destinés au traitement de troubles dépendant de la kinaseInfo
- Publication number
- MA51679A MA51679A MA051679A MA51679A MA51679A MA 51679 A MA51679 A MA 51679A MA 051679 A MA051679 A MA 051679A MA 51679 A MA51679 A MA 51679A MA 51679 A MA51679 A MA 51679A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase
- treatment
- compounds intended
- dependent disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862622702P | 2018-01-26 | 2018-01-26 | |
US201862622626P | 2018-01-26 | 2018-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51679A true MA51679A (fr) | 2020-12-02 |
Family
ID=65685938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051679A MA51679A (fr) | 2018-01-26 | 2019-01-25 | Composés destinés au traitement de troubles dépendant de la kinase |
Country Status (8)
Country | Link |
---|---|
US (2) | US11673897B2 (fr) |
EP (1) | EP3743417A1 (fr) |
JP (1) | JP7480048B2 (fr) |
CN (1) | CN111936487A (fr) |
AU (1) | AU2019212800A1 (fr) |
CA (1) | CA3088198A1 (fr) |
MA (1) | MA51679A (fr) |
WO (1) | WO2019148043A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20230287A (es) * | 2018-01-26 | 2023-07-26 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358) |
WO2022161447A1 (fr) * | 2021-02-01 | 2022-08-04 | 江苏恒瑞医药股份有限公司 | Composé dicarboxamide, son procédé de préparation et son utilisation pharmaceutique |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
EP0817775B1 (fr) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Derives de quinazoline |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
DE69710712T3 (de) | 1996-04-12 | 2010-12-23 | Warner-Lambert Co. Llc | Umkehrbare inhibitoren von tyrosin kinasen |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
EP1415987B1 (fr) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Composes heteroaromatiques azotes pour le traitement des maladies de cancer |
WO2005009387A2 (fr) * | 2003-07-23 | 2005-02-03 | X-Ceptor Therapeutics Inc. | Derives de l'azepine comme agents pharmaceutiques |
DK2392564T3 (da) * | 2003-09-26 | 2014-01-13 | Exelixis Inc | c-Met-modulatorer og anvendelsesfremgangsmåder |
AU2006236508B2 (en) | 2005-04-15 | 2012-02-02 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
CA2970873C (fr) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies |
US20090053236A1 (en) | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
EP2001880A2 (fr) | 2006-03-07 | 2008-12-17 | Array Biopharma, Inc. | Derives heterobicycliques de pyrazole et methodes d'utilisation |
AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
EP2214019A1 (fr) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Marqueurs de tumeurs et leurs utilisations |
EP2213686A1 (fr) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Marqueurs de tumeur et procédés d'utilisation correspondants |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
WO2011051277A1 (fr) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Marqueurs de tumeurs du sein et leurs méthodes d'utilisation |
EP2494362B1 (fr) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Marqueurs de tumeur de la prostate et méthodes d'utilisation |
EP2494361B2 (fr) | 2009-10-26 | 2019-01-09 | Externautics S.p.A. | Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation |
WO2011051276A1 (fr) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Marqueurs de tumeurs du rectum et du côlon, et leurs méthodes d'utilisation |
EP2493916B1 (fr) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Marqueurs associés avec des tumeurs pulmonaires et leur utilisation |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
EP2383578A1 (fr) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Marqueur de tumeur et procédés d'utilisation correspondants |
AU2011278832B2 (en) * | 2010-07-14 | 2014-03-13 | Betta Pharmaceuticals Co., Ltd | Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors |
US8664244B2 (en) | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
WO2014055897A2 (fr) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Anticorps monoclonaux humains anti pd-l1 et procédés d'utilisation |
EP2992017B1 (fr) | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Anticorps dirigés contre la protéine de mort programmée 1 (pd-1) |
US10359428B2 (en) | 2013-06-14 | 2019-07-23 | Externautics S.P.A. | Tumor marker, monoclonal antibodies and methods of use thereof |
KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
JP6696908B2 (ja) | 2014-04-25 | 2020-05-20 | エグゼリクシス, インコーポレイテッド | 肺腺癌の治療方法 |
CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
US20170342033A1 (en) | 2015-06-29 | 2017-11-30 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品(宁波)有限公司 | 一种防老化阳光面料 |
CN107235896B (zh) | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
US10800741B2 (en) | 2017-02-07 | 2020-10-13 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Quinoline compound, preparation method and medical use therefor |
CA3086522A1 (fr) | 2017-12-20 | 2019-06-27 | Angex Pharmaceutical, Inc. | Composes de carbamate et d'uree utilises comme inhibiteurs de multikinases |
CR20230287A (es) | 2018-01-26 | 2023-07-26 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358) |
CR20200355A (es) | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
-
2019
- 2019-01-25 US US16/964,274 patent/US11673897B2/en active Active
- 2019-01-25 CA CA3088198A patent/CA3088198A1/fr active Pending
- 2019-01-25 AU AU2019212800A patent/AU2019212800A1/en active Pending
- 2019-01-25 MA MA051679A patent/MA51679A/fr unknown
- 2019-01-25 JP JP2020540745A patent/JP7480048B2/ja active Active
- 2019-01-25 WO PCT/US2019/015296 patent/WO2019148043A1/fr unknown
- 2019-01-25 EP EP19709144.0A patent/EP3743417A1/fr active Pending
- 2019-01-25 CN CN201980021651.XA patent/CN111936487A/zh active Pending
-
2023
- 2023-04-07 US US18/132,124 patent/US20240150371A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210032263A1 (en) | 2021-02-04 |
AU2019212800A1 (en) | 2020-08-20 |
US20240150371A1 (en) | 2024-05-09 |
JP2021511357A (ja) | 2021-05-06 |
CA3088198A1 (fr) | 2019-08-01 |
WO2019148043A1 (fr) | 2019-08-01 |
EP3743417A1 (fr) | 2020-12-02 |
JP7480048B2 (ja) | 2024-05-09 |
US11673897B2 (en) | 2023-06-13 |
CN111936487A (zh) | 2020-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
MA56114A (fr) | Composés pour le traitement de troubles dépendant de la kinase | |
MA55974A (fr) | Composés triaryles pour le traitement de maladies pd-l1 | |
MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
IL277272A (en) | Rimgepent for CGRP-related disorders | |
MA51738A (fr) | Composés pour le traitement de la douleur | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
MA52761A (fr) | Schéma posologique destiné au traitement de troubles liés à la pi3k | |
MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
DK3432895T3 (da) | Blodpladepelletlysat til anvendelse til behandling af neurologiske forstyrrelser | |
MA52415A (fr) | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines | |
MA47212A (fr) | Méthodes de traitement de troubles neurologiques | |
MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
ES2968222T3 (es) | Agentes inhibidores para la tirosina cinasa de Bruton | |
DK3724173T3 (da) | Forbindelser til behandling af neuromuskulære lidelser | |
MA51679A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
MA53664A (fr) | Composés destinés au traitement de certaines leucémies | |
MA53817A (fr) | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv | |
MA54741A (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques |